BRRG.F Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.025 |
| 52 Week High | NOK 0.025 |
| 52 Week Low | NOK 0.025 |
| Beta | 1.42 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.36% |
| 5 Year Change | n/a |
| Change since IPO | -99.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRRG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -1.1% |
| 1Y | n/a | 29.2% | 40.3% |
Return vs Industry: Insufficient data to determine how BRRG.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BRRG.F performed against the US Market.
Price Volatility
| BRRG.F volatility | |
|---|---|
| BRRG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BRRG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BRRG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 25 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.
BerGenBio ASA Fundamentals Summary
| BRRG.F fundamental statistics | |
|---|---|
| Market cap | US$58.12m |
| Earnings (TTM) | -US$18.05m |
| Revenue (TTM) | US$33.56k |
1,732x
P/S Ratio-3.2x
P/E RatioIs BRRG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRRG.F income statement (TTM) | |
|---|---|
| Revenue | NOK 354.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 354.00k |
| Other Expenses | NOK 190.76m |
| Earnings | -NOK 190.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.071 |
| Gross Margin | 100.00% |
| Net Profit Margin | -53,785.59% |
| Debt/Equity Ratio | 0% |
How did BRRG.F perform over the long term?
See historical performance and comparison